• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • English 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Login
View Item 
  •   University of Thessaly Institutional Repository
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • View Item
  •   University of Thessaly Institutional Repository
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
All of DSpace
  • Communities & Collections
  • By Issue Date
  • Authors
  • Titles
  • Subjects

Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappa B ligand levels in women with established osteoporosis treated with teriparatide

Thumbnail
Author
Anastasilakis, A. D.; Goulis, D. G.; Polyzos, S. A.; Gerou, S.; Pavlidou, V.; Koukoulis, G.; Avramidis, A.
Date
2008
DOI
10.1530/eje-07-0528
Keyword
PARATHYROID-HORMONE 1-34
RANKL MESSENGER-RNA
POSTMENOPAUSAL WOMEN
IN-VIVO
CIRCULATING OSTEOPROTEGERIN
PRIMARY HYPERPARATHYROIDISM
BONE
METABOLISM
EXPRESSION
CELLS
ASSOCIATION
Endocrinology & Metabolism
Metadata display
Abstract
Objective: The mechanisms regulating the anabolic response of the skeleton to intermittent exogenous parathyroid hormone (PTH) administration are not fully elucidated. The aim of this prospective study was to evaluate the acute effect (up to 1 month) of teriparatide (TPTD: human recombinant PTH 1-34) on serum levels of osteoprotegerin (OPG) and receptor activator for nuclear factor-kappa B ligand (RANKL) in women with established osteoporosis. Design: Twenty-three postmenopausal Caucasian women with established osteoporosis (mean age 66.7 +/- 1.6 years) received daily injections of 20 mu g TPTD for 12 months. Methods: Serum samples for total calcium (Ca), phosphate, alkaline phosphatase, N-terminal propeptide of type I collagen, intact PTH (iPTH), OPG, and RANKL were obtained at baseline, 1 h, 1 day, and 1 month after initiation of therapy. Lumbar spine bone mineral density (BMD) was measured before and 12 months after TPTD treatment. Results: Serum total Ca increased and iPTH gradually decreased with TPTD treatment. Serum OPG levels remained unchanged, while RANKL increased gradually during the study (P < 0.001). There was no correlation between OPG or RANKL and BMD changes or iPTH levels. Conclusions: TPTD therapy in women with postmenopausal osteoporosis results in acute increase in serum RANKL levels but does not affect serum OPG. These changes may reflect an increase in the number of active osteoblasts with therapy and might be responsible for the acceleration of bone turnover rate that characterizes TPTD.
URI
http://hdl.handle.net/11615/25538
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19672]
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister (MyDspace)
Help Contact
DepositionAboutHelpContact Us
Choose LanguageAll of DSpace
EnglishΕλληνικά
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013